VACCINATION OF PREMATURE/LOW-BIRTH-WEIGHT CHILDREN
https://doi.org/10.15690/pf.v10i4.752
Abstract
The article is dedicated to vaccination of premature/low-birth-weight children. This is an extremely topical issue as these children are the most susceptible to infectious diseases, including controlled diseases; however, specialists are reluctant to vaccinate them due to possible unfavorable responses of premature bodies to the introduction of an immunotropic agent. The authors present peculiarities of immune response of premature infants, of the T-cell level in particular, which are to be taken into account during vaccination. Special attention is given to the safety of vaccines – risk of development of apneic episodes with/without bradycardia, their influence on the frequency of obstructive episodes and effect of simultaneous introduction of several vaccines on body. Moreover, the article sets forward issues of immunogenicity and reactogenicity of various vaccines when administered to low-birth-weight children.
About the Author
V. K. Tatochenko
Scientific Center of Children’s Health, Moscow
Russian Federation
PhD, Professor, chief research fellow of the RAMS SCCH
Russian Federation
PhD, Professor, chief research fellow of the RAMS SCCH
References
1. Langkamp D. L., Davis J. P. Increased risk of reported pertussis and hospitalization associated with pertussis in low birth weight children. J. Pediatr. 1996; 128: 654–9.
2. Pneumococcal conjugate vaccine for childhood immunization - WHO recommendations. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2007; 4 (5): 6–10.
3. Namazova L.S., Botvin'eva V.V., Gaivoronskaya A.G., Filyanskaya E.G. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2008; 5 (5): 10–12.
4. Namazova-Baranova L.S. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2012; 9 (4): 15–24.
5. Levy O., Zarember K. A., Roy R. M., et al. Selective impairment of TLR-mediated innate immunity in human newborns: neonatal blood plasma reduces monocyte TNF-alpha induction by bacterial lipopeptides, lipopolysaccharide, and imiquimod, but preserves the response to R-848. J. Immunol. 2004; 173 (7): 4627–4634.
6. Studenikin V. M. Stanovlenie limfoidnoi sistemy i osobennosti membrannykh retseptorov immunokompetentnykh kletok v rannem ontogeneze. Avtoref. dis. … dokt. med. nauk [Formation of the Lymphoid System and Features of Membrane Receptors of Immune Cells in Early Ontogeny. Author’s abstract]. Moscow, 1997.
7. Berrington J. E., Barge D., Fenton A. C., Cant A. J., Spickett G. P. Lymphocyte subsets in term and significantly preterm UK infants in the first year of life analysed by single platform flow cytometry. Clin. Exp. Immunol. 2005; 140 (2): 289–292.
8. Turti T.V., Semikina E.L., Namazova L.C. Voprosy sovremennoi pediatrii = Current pediatrics. 2006; 5 (1): 5–23.
9. Klein N. P., Gans H. A., Sung P. et al. Preterm infants' T cell responses to inactivated poliovirus vaccine. J. Infect. Dis. 2010; 201 (2): 214–222.
10. Baxter D. Impaired functioning of immune defenses to infection in premature and term infants and their implications for vaccination. Human Vaccines. 2010; 6 (6): 494–505.
11. Esposito S., Fumagalli M., Principi N. Immunogenicity, safety and tolerability of vaccinations in premature infants. Expert Rev Vaccines. 2012; 11 (10): 1199–209.
12. van den Berg J. P., Westerbeek E. A. M., van der Klis F. R. M. et al. Transplacental transport of IgG antibodies to preterm infants: A review of the literature. Hum. Vaccin. 2011; 87 (2): 67–72.
13. Bonhoeffer J., Siegrist C.A., Heath P.T. Immunisation of premature infants. Arch. Dis. Child. 2006; 9: 929–935.
14. Sen S., Cloete Y., Hassan K., Buss P. Adverse events following vaccination in premature infants. Acta Paediatr. 2001; 90 (8): 916–920.
15. D’Angio C. Active immunization of premature and low birthweight infants: A review of immunogenicity, efficacy, and tolerability. Paediatr. Drugs. 2007; 9 (1): 17–32.
16. Schloesser R., Fischer D., Otto W., Rettwitz-Volk W., Herden P., Zielen S. Safety and immunogenicity of an acellular pertussis vaccine in premature infants. Pediatrics. 1999; 103 (5): e60.
17. Vazquez L., Garcia F., Ruttimann R. et al. Immunogenicity and reactogenicity of DTPa-HBV–IPV/Hib vaccine as primary and booster vaccination in low-birth-weight premature infants. Acta Paediatr. 2008; 97 (9): 1243–9.
18. Furck A. K., Richter J. W., Kattner E. Very low birth weight infants have only few adverse events after timely immunization. J. Perinatol. 2010; 30 (2): 118–21.
19. Hacking D. F., Davis P. G., Wong E., Wheeler K., McVernon J. Frequency of respiratory deterioration after immunisation in preterm infants. J. Paediatr. Child Health. 2010; 46 (12): 742–748.
20. Klein N. P., Massolo M. L., Greene J., Dekker C. L., Black S., Escobar G. J. et al. Risk factors for developing apnea after immunization in the Neonatal Intensive Care Unit. Pediatrics. 2008; 121 (3): 463–9.
21. Carbone T., McEntire B., Kissin D. еt al. Absence of an increase in cardiorespiratory events after diphtheria-tetanus-acellular pertussis immunization in preterm infants: a randomized, multicenter study. Pediatrics. 2008; 121 (5): e1085–90.
22. Clifford V., Crawford N. W., Royle J. et al. Recurrent apnoea post immunisation: Informing re-immunisation policy. Vaccine. 2011; 29 (34): 5681–5687.
23. Schulzke S., Heininger U., Lucking-Famira M., Fahnenstich H. Apnoea and bradycardia in preterm infants following immunization with pentavalent or hexavalent vaccines. Eur. J. Pediatr. 2005; 164 (7): 432–5.
24. Pfister R. E., Aeschbach V., Niksic-Stuber V., Martin B. C., Siegrist C.A. Safety of DTaP-based combined immunization in verylow-birth-weight premature infants: Frequent but mostly benign cardiorespiratory events. J. Pediatr. 2004; 145 (1): 58–66.
25. Botham S. J., Isaacs D., Henderson-Smart D. J. Incidence of apnoea and bradycardia in preterm infants following DTPw and Hib immunization: a prospective study. J. Paediatr. Child Health. 1997; 33 (5): 418–21.
26. American Academy of Pediatrics, Committee on Infectious Diseases. Red Book. 19th ed. Evanston, IL: AAP. 1982. Р. 200–2.
27. Pourcyrous M., Korones S., Arheart K. I., Bada H. S.
28. Primary immunization of premature infants with gestational age < 35 weeks: cardiorespiratory complications and C-reactive protein responses associated with administration of single and multiple separate vaccines simultaneously. J. Pediatr. 2007; 151: 167–72.
29. Mullooly J. P., Schuler R., Mesa J. et al. Wheezing lower respiratory disease and vaccination of premature infants. Vaccine. 2011; 29 (44): 611–7617.
30. Aued Perin М. С., Schlindwein С. F., de Moraes-Pinto M. I. et al. Immune response to tetanus booster in infants aged 15 months born prematurely with very low birth weight. Vaccine. 2012; 30 (46): 6521–6526.
31. Slack M. H., Schapira D., Thwaites R. J. et al. Acellular pertussis vaccine given by accelerated schedule: response of preterm infants. Arch Dis Child Fetal Neonatal Ed. 2004; 89 (1): 57–60.
32. Esposito S., Faldella G., Giammanco A. et al. Long-term pertussis-specific immune responses to a combined diphtheria, tetanus, tricomponent acellular pertussis and hepatitis B vaccine in pre-term infants. Vaccine. 2002; 20 (23–24): 2928–2932.
33. Vermeulen F., Verscheure V., Damis E. et al. Cellular immune responses of preterm infants after vaccination with whole-cell or acellular pertussis vaccines. Clin. Vaccine Immunol. 2010; 17 (2): 258–262.
34. Slack M. H., Cade S., Schapira D. DT5aP-Hib-IPV and MCC vaccines: preterm infants' response to accelerated immunisation. Arch. Dis. Child. 2005; 90 (4): 338–341.
35. Adenyi-Jones S. C., Faden H., Ferdon M. B. et al. Systemic and local immune responses to enhanced-potency inactivated poliovirus vaccine in premature and term infants. J. Pediatr. 1992; 120 (5): 686–689.
36. D'Angio C. T., Maniscalco W. M., Pichichero M. E. Immunologic response of extremely premature infants to tetanus, Haemophilus influenzae, and polio immunizations. Pediatrics. 1995; 96 (1 Pt. 1): 18–22.
37. Losonsky G. A., Wasserman S. S., Stephens I. et al. Hepatitis B vaccination of premature infants: a reassessment of current recommendations for delayed immunization. Pediatrics. 1999; 103 (2): E14.
38. Omenaca F., Garcia-Sicilia J., Garcia-Corbeira P., Boceta R. et al. Response of preterm newborns to immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio and Haemophilus influenzae type b vaccine: first experiences and solutions to a serious and sensitive issue. Pediatrics. 2005; 16 (6): 1292–8.
39. Kristensen K., Gyhrs A., Lausen B. et al. Antibody response to Haemophilus influenzae type b capsular polysaccharide conjugated to tetanus toxoid in preterm infants. Pediatr Infect Dis J. 1996; 15 (6): 525–529.
40. Heath P. T., Booy R., McVernon J. et al. Hib vaccination in infants born prematurely. Arch Dis Child. 2003 Mar; 88 (3): 206–10.
41. Omenaca F., Garcia-Sicilia J., Garcia-Corbeira P. et al. Antipolyribosyl ribitol phosphate response of premature infants to primary and booster vaccination with a combined diphtheriatetanus-acellular pertussis-hepatitis B-inactivated polio virus/Haemophilus influenzae type b vaccine. Pediatrics. 2007; 119 (1): e179–85.
42. Omenaca F., Garcia-Sicilia J., Boceta R. et al. Antibody persistence and booster vaccination during the second and fifth years of life in a cohort of children who were born prematurely. Pediatr Infect Dis J. 2007 Sep; 26 (9): 824–9.
43. Szynczewska Е., Chlebna-Sokol D. Immunogenicity and safety of heptavalent conjugate vaccine against Streptococcus pneumoniae in pre-term polish infants. Vaccine. 2011; 29: 7107– 7113.
44. Esposito S., Pugnib L., Bosisa S. et al. Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre- and fullterm infants. Vaccine. 2005; 23: 1703–1708.
45. D’Angio С. Т., Heyne R. J., ’Shea M. et al. Heptavalent pneumococcal conjugate vaccine immunogenicity in very-low-birthweight, premature infants. Pediatr Infect Dis J. 2010; 29 (7): 1–7.
46. Shinefield H., Black S., Ray P. et al. Efficacy, immunogenicity and safety of heptavalent pneumococcal conjugate vaccine in low birth weight and preterm infants. Pediatr Infect Dis J. 2002; 21 (3): 182–6.
47. Ruckinger S., van der Linden M., von Kries1 R. et al. Effect of heptavalent pneumococcal conjugate vaccination on invasive
48. pneumococcal disease in preterm born infants. BMC Infectious Diseases. 2010; 10: 12. Doi: 10.1186/1471-2334-10-12.
49. Omenaca F., Merino J. M., Tejedor J. C. et al. Immunization of preterm infants with 10-valent pneumococcal conjugate vaccine. Pediatrics. 2011; 128 (2): e290–298.
50. D'Angio C. T., Heyne R. J., Duara S. et al. Premature Infant Vaccine Collaborative. Immunogenicity of trivalent influenza vaccine in extremely low-birth-weight, premature versus term infants. Pediatr Infect Dis J. 2011; 30 (7): 570–574.
51. Omenaca F., Sarlangue J., Szenborn L. et al. ROTA-054 Study Group Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European infants: a randomized Phase IIIb study. Pediatr Infect Dis J. 2012; 31 (5): 487–493.
52. Smith C. K., McNeal M. M., Meyer N. R. et al. Rotavirus shedding in premature infants following first immunization. Vaccine. 2011; 29 (45): 8141–8146.
53. D'Angio C. T., Boohene P. A., Mowrer A. et al. Measles-mumpsrubella and varicella vaccine responses in extremely preterm infants. Pediatrics. 2007; 119 (3): e574–579.
Review
For citations:
Tatochenko V.K. VACCINATION OF PREMATURE/LOW-BIRTH-WEIGHT CHILDREN. Pediatric pharmacology. 2013;10(4):30-36. https://doi.org/10.15690/pf.v10i4.752
Views:
4141
Email this article 